Clinical Trials Active But Not Recruiting

Breakdown for each trial:
• Name of trial
• Short summary
• Countries recruiting
• Link to trial page on clinicaltrials.gov
• Trial Status

A Trial of Eltrombopag or Intravenous Immune Globulin Before Surgery for Immune Thrombocytopenia Patients

This is a study to investigate if eltrombopag can be used instead of Intravenous Immune Globulin (IVIG) in patients with ITP, to adequately raise their platelet count when they undergo minor or major surgery. Eltrombopag is a daily, oral pill approved for treatment of ITP. IVIG is a blood product frequently used to treat ITP. Patients with ITP who need surgery have to get treatment to increase their platelet count. IVIG is commonly used for this purpose but eltrombopag may be more effective and convenient for patients.

Canada

https://clinicaltrials.gov/ct2/show/NCT01621204?recrs=a&cond=ITP&draw=2&rank=18

Active, but not recruiting

A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA) (SOAR)

Idiopathic thrombocytopenia purpura (ITP) is the destruction of platelets in the body. Autoimmune hemolytic anemia (AIHA) is a rare disease characterized by the body’s premature destruction of red blood cells (hemolysis). Both of these conditions are autoimmune disorders, which means that the body’s immune system malfunctions and attacks healthy blood cells. These two disorders can occur at the same time (destruction of both red blood cells and platelets) or one disorder develops after the other. Evans syndrome is the combination of AIHA with ITP. The cause of Evans syndrome is currently unknown.

A Phase 2 clinical study of an investigational drug is seeking AIHA patients who meet certain criteria.

USA, Canada

https://clinicaltrials.gov/ct2/show/study/NCT02612558

Active, but not recruiting

Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

The purpose of this study is to determine whether fostamatinib is safe and effective in treating patients with persistent/chronic Immune Thrombocytopenic Purpura (ITP) over a 5 year period.

USA, Australia, Austria, Bulgaria, Canada, Czechia, Denmark, Hungary, Italy, Netherlands, Norway, Poland, Romania, Spain, United Kingdom

https://clinicaltrials.gov/ct2/show/NCT02077192?recrs=d&cond=ITP&rank=3

Active, but not recruiting

Eltrombopag in Second Line Adult Primary Immune Thrombosytopenia

A clinical study to evaluate the efficacy of eltrombopag in adult patients diagnosed with primary immune thrombocytopenia as first treatment to address the disease. This is a prospective, multicenter phase II trial designed to evaluate the activity of Eltrombopag second line treatment in adult patients with primary Immune Thrombocytopenia (ITP) not responsive or in relapse after a full first line steroids treatment (prednisone or dexamethasone) ± Intravenous Immune Globulin (IVIG).

Italy

https://clinicaltrials.gov/ct2/show/study/NCT02402998?recrs=d&cond=ITP&rank=6

Active, but not recruiting

Newly Diagnosed Immune Thrombocytopenia Testing the Standard Steroid Treatment Against Combined Steroid & Mycophenolate (FLIGHT)

This is a study of two treatment pathways [Standard steroid treatment versus combined steroid and Mycophenolate (MMF)] for subjects with newly diagnosed Immune Thrombocytopenia (ITP). This study examines if it would benefit more patients if everyone takes MMF at diagnosis instead of current practice (waiting for the illness to come back).

United Kingdom

https://clinicaltrials.gov/ct2/show/NCT03156452?recrs=a&cond=ITP&draw=4&rank=27

Active, but not recruiting

Immunomodulation With Romiplostim in Young Adults With ITP (iROM)

The study aims to investigate immunomodulatory effects of Thrombopoietin-Receptor Agonist (TPO-RA) in patients with primary ITP, who failed first-line therapy or who became intolerant to it. It is hypothesized that the early phase of this autoimmune disease may exhibit a stronger immunomodulatory potential in response to a stimulus, such as romiplostim. This study examines if such a process may subsequently be capable to induce regulatory mechanisms or tolerance.

Switzerland

https://clinicaltrials.gov/ct2/show/NCT02760251?recrs=a&cond=ITP&draw=1&rank=7

Active, but not recruiting

BBB Cleveland logo GuideStar Seal NORD Member Badge 2018THSNA logo